8-K: Labcorp to Acquire Oncology Testing Assets from OPKO Health's BioReference Health for Up to $225 Million

Labcorp is set to acquire BioReference Health's oncology and oncology-related clinical testing services for up to $225 million, enhancing Labcorp's oncology leadership and expanding access to its services.

Summary

• Labcorp has agreed to acquire select oncology and oncology-related clinical testing assets from OPKO Health's BioReference Health for up to $225 million.
• The deal includes $192.5 million payable at closing and up to $32.5 million in an earnout based on performance.
• The acquired assets generate approximately $85 million to $100 million in annual revenue.
• BioReference Health will retain its core clinical testing services in New York and New Jersey, and its 4Kscore franchise, which generated approximately $300 million in revenue for 2024.
• The transaction is expected to close in the second half of 2025 and is projected to be accretive to Labcorp's earnings in year one.

Sentiment

Score: 8

Explanation: The document presents a positive outlook for both Labcorp and OPKO Health, with the acquisition expected to be accretive to Labcorp's earnings and unlock additional value for OPKO. The deal appears to be strategically sound and financially beneficial for both parties.

Positives

• The acquisition is expected to be accretive to Labcorp's earnings in the first year.
• Labcorp will expand its oncology testing portfolio and increase its market presence.
• BioReference Health will streamline operations and focus on its core clinical testing services and urology franchise.
• The transaction is expected to unlock additional value for OPKO Health.

Risks

• The transaction is subject to customary closing conditions and regulatory approvals, which may cause delays or prevent the deal from closing.
• The earnout payment is contingent on the performance of the acquired assets, which may not be achieved.
• There are forward-looking statements regarding the anticipated impact of the transaction, which are subject to various factors and uncertainties that could affect actual results.

Future Outlook

The transaction is expected to provide patients, physicians, and customers with greater access to Labcorp's services and is projected to be accretive to Labcorp's earnings in year one. BioReference Health will maintain its core clinical testing services and expand its urology franchise.

Management Comments

• Mark Schroeder, EVP and President, Diagnostics Laboratories and Chief Operations Officer, Labcorp, stated that the acquisition provides greater access to Labcorp's services and reinforces their commitment to advancing cancer care.
• Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO, stated that the transaction is an important step to streamline BioReference Health's operations and unlock additional value.

Industry Context

This acquisition reflects a trend of consolidation in the laboratory services industry, with larger players like Labcorp seeking to expand their capabilities and market share in specialized areas such as oncology testing. It also highlights the growing importance of diagnostics in cancer care.

Comparison to Industry Standards

• Labcorp is a major player in the diagnostics industry, competing with companies like Quest Diagnostics.
• The acquisition of BioReference Health's oncology assets is similar to other strategic acquisitions made by Labcorp to expand its service offerings.
• The purchase price of up to $225 million is within the range of typical valuations for similar assets in the diagnostics industry.

Stakeholder Impact

• Patients and physicians are expected to benefit from greater access to Labcorp's comprehensive laboratory services.
• Labcorp employees will welcome new colleagues from BioReference Health.
• OPKO Health shareholders are expected to benefit from the streamlined operations and unlocked value of BioReference Health.

Next Steps

• The transaction is subject to customary closing conditions and regulatory approvals.
• The parties will work to finalize the acquisition and integrate the acquired assets into Labcorp's operations.

Key Dates